U.S. Markets closed

Is It Time To Buy ACADIA Pharmaceuticals Inc (ACAD)?

Collin Greene

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), a biotechnology company based in United States, saw significant share price volatility over the past couple of months on the NasdaqGS, rising to the highs of $39.14 and falling to the lows of $30.94. This high level of volatility gives investors the opportunity to enter into the stock, and potentially buy at an artificially low price. A question to answer is whether ACAD’s current trading price of $32.55 reflective of the actual value of the mid-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at ACAD’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change. View our latest analysis for ACADIA Pharmaceuticals

What’s the opportunity in ACAD?

ACAD is currently overpriced based on my relative valuation model. In this instance, I’ve used price-to-book ratio (PB) ratio given that there is not enough information to reliably forecast the stock’s cash flows, and its earnings doesn’t seem to reflect its true value. I find that ACAD’s ratio of 9.6x is above its peer average of 3.7x, which suggests the stock is expensive compared to the biotechnology industry. If you like the stock, you may want to keep an eye out for a potential price decline in the future. Since ACAD’s share price is quite volatile, this could mean it can sink lower (or rise even further) in the future, giving us another chance to invest. This is based on its high beta, which is a good indicator for how much ACAD moves relative to the rest of the market.

What does the future of ACAD look like?

NasdaqGS:ACAD Future Profit Nov 8th 17

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. ACAD’s earnings over the next few years are expected to increase by 47.60%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value.

What this means for you:

Are you a shareholder? ACAD’s optimistic future growth appears to have been factored into the current share price, with shares trading above its fair value. However, this brings up another question – is now the right time to sell? If you believe ACAD should trade below its current price, selling high and buying it back up again when its price falls towards its real value can be profitable. But before you make this decision, take a look at whether its fundamentals have changed.

Are you a potential investor? If you’ve been keeping tabs on ACAD for some time, now may not be the best time to enter into the stock. The price has surpassed its industry peers, which means it is likely that there is no more upside from mispricing. However, the positive outlook is encouraging for ACAD, which means it’s worth diving deeper into other factors in order to take advantage of the next price drop.

Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on ACADIA Pharmaceuticals. You can find everything you need to know about ACAD in the latest infographic research report. If you are no longer interested in ACADIA Pharmaceuticals, you can use our free platform to see my list of over 50 other stocks with a high growth potential.


To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned.